Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2011 June;63(3) > Minerva Ginecologica 2011 June;63(3):275-86

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

  NEW INSIGHTS INTO GYNECOLOGY IN 2011


Minerva Ginecologica 2011 June;63(3):275-86

language: English

Selective estrogen receptor modulators: the future in menopausal treatment

Palacios S.

DPalacios Institute of Woman’s Health Madrid, Spain


PDF  


The results of hormone therapy (HT) studies have changed the perception of HT benefits and risks. Selective estrogen receptor modulators (SERMs) represent drugs with a tissue-specific estrogen receptor agonist/antagonist activity and they are an alternative to HT. Each SERM stimulates and blocks different genes with different biological responses. Established SERMs or second generation are tamoxifen and raloxifene. Both SERMs have positive effects on breast, bone and lipids, but with an increased risk for venous thromboembolism and hot flushes. None of these SERMs has shown a preventive effect on non-vertebral fractures. At present, there is a new generation of SERMs (third generation: bazedoxifene, lasofoxifene and ospemifene) which has completed phase III clinical trials and has been submitted to the Health Regulatory Authorities for approval. A new concept, tissue selective estrogen complex (TSEC), has the potential to demonstrate the benefits of SERMs along with the additional benefits of estrogens. A long road to the ideal SERM still remains, but new SERMs represent an attractive new menopause treatment.

top of page

Publication History

Cite this article as

Corresponding author e-mail

ipalacios@institutopalacios.com